Bayer seeks to block Nexavar generic at Delaware court
Bayer and Onyx Pharmaceuticals have sued generic drug maker Mylan in an attempt to stop it from developing a version of liver cancer drug Nexavar (sorafenib tosylate).
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
30 October 2017 Bayer Healthcare and Mylan have settled their differences over a generic version of Bayer’s liver cancer drug Nexavar (sorafenib tosylate).
30 October 2017 Bayer Healthcare and Mylan have settled their differences over a generic version of Bayer’s liver cancer drug Nexavar (sorafenib tosylate).
30 October 2017 Bayer Healthcare and Mylan have settled their differences over a generic version of Bayer’s liver cancer drug Nexavar (sorafenib tosylate).